Related Experiment Video

Updated: Jun 30, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.6K

Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal

Maryam Soleimani1, Marisa Thi2, Sajjad Janfaza3

  • 1Division of Medical Oncology, British Columbia Cancer-Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.

Scientific Reports
|April 13, 2024
PubMed

Insights

Predicting response to immune checkpoint inhibitors (ICI) in advanced renal cell carcinoma (RCC) is crucial. Lower levels of microRNA155-3p (miR155) in plasma predict better response to ICI therapy in metastatic RCC patients.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Predictive biomarkers for immune checkpoint inhibitor (ICI) therapy in advanced renal cell carcinoma (RCC) are needed.
  • The tumor microenvironment and systemic immune responses are complex and difficult to interpret.
  • MicroRNAs are key regulators of gene expression with potential immunomodulatory roles.

Purpose of the Study:

  • To investigate immune-specific extracellular vesicle (EV) microRNAs in the plasma of metastatic RCC (mRCC) patients before ICI treatment.
  • To identify potential microRNA biomarkers associated with response to ICI therapy.

Main Methods:

  • Plasma samples were collected from mRCC patients before initiating ICI therapy.
  • Extracellular vesicle (EV)-derived microRNAs were analyzed.
  • Levels of specific microRNAs, including microRNA155-3p (miR155), were quantified and compared between responders and non-responders.

Main Results:

  • Significantly lower levels of microRNA155-3p (miR155) were observed in patients who responded to ICI therapy compared to non-responders.
  • miR155 possesses known immunomodulatory properties, offering a potential biological explanation for the observed association.

Conclusions:

  • MicroRNAs, specifically miR155, show potential as predictive biomarkers for ICI therapy response in advanced RCC.
  • Further research into microRNAs could enhance immunotherapy strategies for RCC patients.

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.5K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.3K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...